Clinical trials: Severe Allergic Asthma
Asthma
A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma
This is a continued access protocol to provide subjects who have completed Genentech, Inc. Study Q2143g, Q2195g, or Q2461g or Novartis Pharmaceuticals Corporation Study CIGE025 0010E1 with continued Xolair treatment.
- Trial name
- NCT00109200
- Testing
- Xolair (omalizumab)
- Sponsor
- Genentech, Inc.
Allergic Asthma, Severe Eosinophilic Asthma
Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma
Chronic airway inflammation rich in eosinophils is an important feature seen in asthma. Airway and blood eosinophilia is associated with increased rates of asthma exacerbations and more intense treatment.
- Trial name
- NCT04542902
- Testing
- Dermatophagoides pteronyssinus allergen, Blood sampling, Bronchial challenge with allergen
- Where
- Lithuania
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Lithuanian University of Health Sciences
Allergic Bronchopulmonary Aspergillosis, ABPA
Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma
An open-label study will evaluate effects of Depemokimab in the treatment of severe eosinophilic asthma in patients with allergic bronchopulmonary aspergillosis
- Conditions
- Allergic Bronchopulmonary Aspergillosis, ABPA, Severe Eosinophilic Asthma
- Trial name
- NCT07828327
- Testing
- Depemokimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Qianfoshan Hospital
Allergic Asthma
A Study to Evaluate the Safety and Efficacy of HAE1 in Subjects With Moderate to Severe Allergic Asthma
This is a Phase II, multicenter, randomized, double blind, placebo controlled, multiple-dose study designed to evaluate the efficacy, safety, and tolerability of subcutaneously administered HAE1 in subjects 12-75 years old with…
- Trial name
- NCT00406965
- Testing
- HAE1 (PRO98498)
- Volunteers
- 50 people
- Sponsor
- Genentech, Inc.
Asthma
Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
A substance called immunoglobulin E (IgE), which is naturally produced by our body, has a key role in generating asthma attacks.
- Trial name
- NCT00079937
- Testing
- Omalizumab, Fluticasone
- Where
- 56 sites in United States
- Volunteers
- 628 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients
This study will assess the safety and tolerability of long-term treatment with omalizumab plus current asthma therapy in patients who participated in and successfully completed the treatment period of study CIGE025IA04E1.
- Trial name
- NCT00482508
- Testing
- Omalizumab
- Volunteers
- 95 people
- Sponsor
- Novartis
Asthma Persistent, Asthma, Allergic
Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma
The aim of this study is to determine and compare serum cytokine levels of six different severe asthma inflammatory phenotypes differentiated by their atopy, peripheral eosinophilia and/or chronic rhinosinusitis and/or nasal…
- Conditions
- Asthma Persistent, Asthma, Allergic, Eosinophilic Asthma, Chronic Rhinosinusitis (Diagnosis)
- Trial name
- NCT03563521
- Where
- Turkey (Türkiye)
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- TC Erciyes University
Asthma
Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma
This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe…
- Trial name
- NATAIR (NCT01007149)
- Testing
- omalizumab
- Where
- 10 sites in France
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)
This study is multicenter, double-blinded parallel group design, where participants with moderate to severe asthma with AFAD will be enrolled.
- Trial name
- NCT03393806
- Testing
- GSK3772847
- Where
- 18 sites in France, Netherlands and 2 more
- Volunteers
- 17 people
- Sponsor
- GlaxoSmithKline
Lung Disease
Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair
The purpose of this study is to study the effects of Xolair using non-invasive techniques from the expired gas of patients with moderate to severe allergic asthma.
- Trial name
- NCT00139152
- Testing
- Xolair
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Creighton University
Severe Allergic Asthma
Correlation Between IgE Parameters and the Response to Omalizumab in Subjects With Severe Asthma
Omalizumab is an anti-IgE recombinant humanized monoclonal antibody.The efficacy and tolerability of omalizumab have been demonstrated in patients with moderate-to-severe and allergic (IgE-mediated) asthma.
- Trial name
- OM-2009-XO (NCT01002976)
- Where
- Israel
- Sponsor
- Carmel Medical Center
Allergic Bronchopulmonary Aspergillosis, Severe Asthma
Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis
An open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis
- Conditions
- Allergic Bronchopulmonary Aspergillosis, Severe Asthma, ABPA
- Trial name
- NCT07530770
- Testing
- Fasenra
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Qianfoshan Hospital
Allergic Asthma
Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma
This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy and safety of FB825 in adult patients with moderate-to-severe allergic asthma.
- Trial name
- NCT05008965
- Testing
- FB825
- Where
- 13 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- Oneness Biotech Co., Ltd.
Severe Allergic Asthma
Nocturnal TLA for Severe Allergic Asthma After Withdrawal of Omalizumab Therapy
This is a randomized, controlled study with a 48-week treatment phase to determine the clinical efficacy of temperature controlled laminar flow device (TLA, Airsonett™) in the patients with severe allergic asthma who are…
- Trial name
- NCT03480815
- Testing
- Nocturnal Temperature Controlled Laminar Flow Device, None Device
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- Chang Gung Memorial Hospital
Asthma
Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
This study aimed to determine the efficacy and safety of QAW039 150 mg and QAW039 450 mg, compared with placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016)…
- Trial name
- NCT02555683
- Testing
- QAW039
- Where
- 234 sites in United States, Argentina and 25 more
- Volunteers
- 894 people
- Sponsor
- Novartis Pharmaceuticals
ALLERGIC ASTHMA
A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy
The researcher proposes to assess levels of sputum inflammatory markers (eosinophils, eosinophil cationic protein (ECP), neutrophils IL-8) before and while on anti-IgE therapy in a pediatric population of moderate to severe…
- Trial name
- NCT00283504
- Testing
- ANTI-IGE THERAPY (XOLAIR)
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of The King's Daughters
Asthma
Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma
The purpose of this study is to determine the effect of omalizumab, compared to placebo, on clinically significant asthma exacerbation rates in adolescents and adults with asthma.
- Trial name
- NCT00046748
- Testing
- Omalizumab
- Volunteers
- 484 people
- Sponsor
- Novartis Pharmaceuticals
Asthma Acute, Exacerbation of Allergic Asthma
Nebulized Ketamine for Severe Asthma Attacks in Children
This is a double-blinded, randomised, placebo-controlled trial enrolling 60 children aged 1 to 13 years with severe asthma exacerbation. All participants will receive standard therapy.
- Trial name
- NCT07728851
- Testing
- Ketamine (1 mg/kg)
- Where
- Oman
- Volunteers
- 60 people
- Sponsor
- Sultan Qaboos University
Allergic Asthma
Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients
This is a multicenter, randomized, masked, active and placebo controlled, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetics of LP-003 injection in adult patients with moderate to severe persistent…
- Trial name
- NCT07342803
- Testing
- LP-003 Injection, Omalizumab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Longbio Pharma
Asthma
Short Treatment with Omalizumab for Severe Asthma
The optimal duration of the treatment by OMA remains unclear when asthma is well controlled. Data suggest that a large part of patients with well controlled asthma can discontinue OMA therapy without any asthma control…
- Trial name
- SHORTEN (NCT04763447)
- Testing
- Attempt to withdrawal OMA treatment, Continuation of OMA treatment
- Where
- France
- Volunteers
- 234 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris